Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis (FILOSOPHY)

Alfasigma

Status: Active, not recruiting

Conditions: Rheumatoid Arthritis

Treatments: Drug: Filgotinib

Study type: Observational

Funder types: Industry

Identifiers

NCT04871919

48323 (Other Identifier)

GLPG0634-CL-401

Details and patient eligibility

About

An observational study to describe the effectiveness, safety, and patient-reported outcomes in patients with moderate to severe active rheumatoid arthritis (RA) receiving filgotinib in real-world setting.

Enrollment: 1,304 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged ≥ 18 years with a diagnosis of moderate to severe active RA being prescribed filgotinib in accordance with the local standard of care and product label for the first time.
• Patients must be willing and able to use an electronic device to complete the study patient-reported outcome (PRO).

Exclusion criteria

- Participation in any other interventional or non-interventional study without prior approval from the Medical Monitor. This does not preclude inclusion of patients enrolled to national registries.

Trial design

1,304 participants in 1 patient group

Filgotinib

Description:

Individuals will receive treatment for moderate to severe active rheumatoid arthritis with at least one dose of filgotinib in accordance with the product label

Treatment:

Drug: Filgotinib